The economic and public health impact of intellectual property licensing of medicines for low-income and middle-income countries: a modelling study.

ABSTRACT:

Background

Non-exclusive voluntary licensing that is access-oriented has been suggested as an option to increase access to medicines to address the COVID-19 pandemic. To date, there has been little research on the effect of licensing, mainly focused on economic and supply chain considerations, and not on the benefits in terms of health outcomes. We aimed to study the economic and health effect of voluntary licensing for medicines for HIV and hepatitis C virus (HCV) in low-income and middle-income countries (LMICs).

Methods

A robust modelling framework was created to examine the difference between scenarios, with (factual) and without (counterfactual) a Medicines Patent Pool (MPP) licence for two medicines, dolutegravir and daclatasvir. Data were obtained from MPP licensees,

SUBMITTER: Morin S 

PROVIDER: S-EPMC8809901 | biostudies-literature | 2022 Feb

REPOSITORIES: biostudies-literature